Open-Label Placebo May Reduce Fatigue in Cancer Survivors

Share this content:
Open-Label Placebo May Reduce Fatigue in Cancer Survivors
Open-Label Placebo May Reduce Fatigue in Cancer Survivors

MONDAY, Feb. 12, 2018 (HealthDay News) -- Open-label placebo (OLP) may reduce fatigue in cancer survivors, according to a study published online Feb. 9 in Scientific Reports.

Teri W. Hoenemeyer, Ph.D., from the University of Alabama at Birmingham, and colleagues compared OLP to treatment as usual (TAU) for cancer survivors with fatigue in a 21-day randomized controlled trial. This was followed by a 21-day study in which TAU participants received OLP and OLP participants were followed after discontinuing placebo. Seventy-four cancer survivors who completed treatment six months to 10 years prior to enrollment and reporting at least moderate fatigue were randomized to receive OLP or TAU.

The researchers found that participants randomized to OLP reported a 29 percent improvement in fatigue severity and a 39 percent improvement in fatigue-disrupted quality of life compared to those randomized to TAU. Reductions in fatigue of a similar magnitude were reported for TAU participants who elected to try OLP for 21 days after the main study, with reductions of 23 and 35 percent for fatigue severity and fatigue-disrupted quality of life, respectively.

"OLP may reduce fatigue symptom severity and fatigue-related quality of life disruption in cancer survivors," the authors write.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

U.S. High School Students Report Sport-Linked Concussion

U.S. High School Students Report Sport-Linked Concussion

Overall, 15.1 percent of students reported having at least one concussion in the previous 12 months

Corneal Abnormalities Seen With Down Syndrome

Corneal Abnormalities Seen With Down Syndrome

More than 70 percent of patients in Down syndrome group had traits compatible with keratoconus

Many Childhood CA Survivors Not Concerned About Future Health

Many Childhood CA Survivors Not Concerned About Future ...

Even among those exposed to high radiation doses, one-third not concerned about developing cancer

is free, fast, and customized just for you!




Already a member?

Sign In Now »